The cost, which is confidential & was negotiated for a total of 300 million doses, is somewhat less than the $19.50 a photo the United States agreed to buy a first shipment of 100 million doses of the identical vaccine, in line with what Reuters claimed in November.
The EU document dated Nov. 18 was circulated internally after the EU announced the supply deal of its with Pfizer and the German partner BioNTech of its on Nov. eleven.
The EU drug regulator is expected to determine on Monday on endorsement for the Pfizer vaccine after the shot was authorised in several countries, like Britain and the United States.
On Thursday Belgian state secretary for the spending budget Eva De Bleeker published on Twitter a dining room table with price tags Belgium would shell out pharmaceutical companies for their COVID-19 vaccines. She retracted the content shortly after publishing.
In this dining room table the Pfizer vaccine was indicated as costing Belgium 12 euros ($14.6) per dose, leading many to believe that was the full cost agreed by the EU.
Various other vaccines in the table were also shown with rates lower than rates disclosed by EU solutions.
“There is always a full fee along with a price after delivery,” an EU official required in talks with vaccine makers told Reuters when directed to clarify the difference between the Belgian and EU rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In this public hearing, De Beeker stated Belgium’s budgeted costs were still partial.
Underneath EU advance purchase deals for COVID-19 vaccines, the bloc believes initial payments with companies to secure doses before they’re approved. Following approvals, EU governments can pay the remainder to buy reserved doses.
The EU has not revealed the upfront transaction agreed with Pfizer.
Nonetheless, it stated in October that it paid about 1 billion euros found in downpayments to AstraZeneca, Sanofi and Johnson & Johnson for the shots of theirs, with a further 1.45 billion euros budgeted for upfront payments to Pfizer-BioNTech, Curevac and Moderna.
It has since agreed source deals with all 6 companies and is negotiating a seventh understanding with Novavax.